Bioequivalence of 2 intravenous amiodarone formulations in healthy participants

Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2009, Pages 407-415

  Cushing, Daniel J ^a,d   Adams, Michael P ^b   Cooper, Warren D ^a   Kowey, Peter R ^c   Lipicky, Raymond J ^b  

^a Prism Pharmaceuticals   (United States)

^b Main Line Health Heart Center ^*

^c LANKENAU HOSPITAL   (United States)

^d Prism Pharmaceuticals Inc   (United States)

Author keywords

Bioequivalence; Cyclodextrin; Intravenous amiodarone; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; BENZYL ALCOHOL; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CITRATE TRISODIUM; CITRIC ACID; DEETHYLAMIODARONE; POLYSORBATE 80;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; BLOOD PRESSURE; BLOOD SAMPLING; BODY TEMPERATURE DISORDER; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLATULENCE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS BLOOD;

ADOLESCENT; ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; CYCLODEXTRINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 63849314403     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008330156     Document Type: Article

References (37)

1. Desai AD, Chun S., Sung RJ The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med. 1997; 127: 294-303.
2. Cybulski J., Kulakowski P., Makowska E., Czepiel A., Sikora-Frac M., Ceremuzynski L. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Clin Cardiol. 1996; 19: 563-566.
3. Helmy I., Herre JM, Gee G., et al. Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. J Am Coll Cardiol. 1988; 12: 1015-1022.
4. Kudenchuk PJ Intravenous antiarrhythmic drug therapy in the resuscitation from refractory ventricular arrhythmias. Am J Cardiol. 1999; 84: 52R - 55R.
5. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995; 92: 3264-3272.
6. Levine JH, Massumi A., Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996; 27: 67-75.
7. Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 1995; 92: 3255-3263.
8. Kosinski EJ, Albin JB, Young E., Lewis SM, Leland OS Jr. Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol. 1984; 4: 565-570.
9. US Food and Drug Administration (FDA). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Washington, DC: US Department of Health and Human Services; 2001.
10. Kowey PR, Marinchak RA, Rials SJ, Filart RA Intravenous amiodarone. J Am Coll Cardiol. 1997; 29: 1190-1198.
11. Abraxis Pharmaceutical Products. Amiodarone hydrochloride injection [prescribing information]. Schaumburg, IL: Abraxis Pharmaceutical Products; 2006.
12. Ward GH, Yalkowsky SH Studies in phlebitis: VI. Dilution-induced precipitation of amiodarone HCL. J Parenter Sci Technol. 1993; 47: 161-165.
13. Trissel LA Amiodarone hydrochloride AHFS 24:04.04. In: Trissel LA, ed. Handbook on Injectable Drugs. 14 th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007: 112-118.
14. Chalmers JR, Bobek MB, Militello MA Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health Syst Pharm. 2001; 58: 504-506.
15. Pearson SD, Trissel LA Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm. 1993; 50: 1405-1409.
16. Center for Devices and Radiological Health: US FDA. Safety Assessment of Di(2-ethylhexyl)phthalate (DEHP) Released From PVC Medical Devices. Rockville, MD: Center for Devices and Radiological Health; 2008.
17. Kessler D., Palepu N., Tustian A., et al. A novel amiodarone microemulsion injectable formulation [abstract]. AAPS PharmSci. 2002; 4: W4122.
18. Elhasi S., Astaneh R., Lavasanifar A. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. Eur J Pharm Biopharm. 2007; 65: 406-413.
19. Somberg JC, Timar S., Bailin SJ, et al. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004; 93: 576-581.
20. Cushing D., Lipicky R., Kowey P., Cooper W., Massey B., Gralinski MG PM101, a cyclodextrin-based intravenous formulation of amiodarone, is without hemodynamic effect in anesthetized dogs. Presented at: Annual Meeting of the American Association of Pharmaceutical Scientists; November 17-19, 2008; Atlanta, GA.
21. Souney PF, Cowee J., Mosher G., Cushing DJ Stability of intravenous amiodarone formulations in glass, polyolefin, and polyvinylchloride containers over 72 hours. Presented at: Midyear Clinical Meeting of the American Society of Health System Pharmacists; December 2008; Orlando, FL.
22. Hauschke D., Kieser M., Diletti E., Burke M. Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. Stat Med. 1999; 18: 93-105.
23. US Department of Health and Human Services. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Rockville, MD: US Department of Health and Human Services; 2003.
24. Dhariwal K., Jackson A. Effect of length of sampling schedule and washout interval on magnitude of drug carryover from period 1 to period 2 in two-period, two-treatment bioequivalence studies and its attendant effects on determination of bioequivalence. Biopharm Drug Dispos. 2003; 24: 219-228.
25. Holt DW, Tucker GT, Jackson PR, Storey GC Amiodarone pharmacokinetics. Am Heart J. 1983; 106: 840-847.
26. Ujhelyi MR, Klamerus KJ, Vadiei K., et al. Disposition of intravenous amiodarone in subjects with normal and impaired renal function. J Clin Pharmacol. 1996; 36: 122-130.
27. Vadiei K., O'Rangers EA, Klamerus KJ, et al. Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. J Clin Pharmacol. 1996; 36: 720-727.
28. Vadiei K., Troy S., Korth-Bradley J., Chiang ST, Zimmerman JJ Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J Clin Pharmacol. 1997; 37: 610-617.
29. Krantz JC, Carr CJ, Bird JG, Cook S. Sugar alcohols: XXVI. Pharmacodynamic studies of polyoxyalkylene derivatives of hexitol anhdride partial fatty acid esters. J Pharmacol Exp Ther. 1948; 93: 188-195.
30. Masini E., Planchenault J., Pezziardi F., Gautier P., Gagnol JP Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions. 1985; 16: 470-477.
31. Torres-Arraut E., Singh S., Pickoff AS Electrophysiologic effects of Tween 80 in the myocardium and specialized conduction system of the canine heart. J Electrocardiol. 1984; 17: 145-151.
32. Yasaka WJ, Eichbaum FW, Oga S. Antiarrhythmic effects of solvents: III. Effects of propylene glycol and benzyl alcohol on contractile force of isolated rabbit heart. Cardiovasc Res. 1979; 13: 717-722.
33. Somberg JC, Cao W., Cvetanovic I., Ranade V., Molnar J. Pharmacology and toxicology of a new aqueous formulation of intravenous amiodarone (Amio-Aqueous) compared with Cordarone IV. Am J Ther. 2005; 12: 9-16.
34. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002; 90: 853-859.
35. Loftsson T., Jarho P., Masson M., Jarvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv. 2005; 2: 335-351.
36. Pfizer Inc. VFEND I.V. (voriconazole) for injection, VFEND tablets (voriconazole), VFEND (voriconazole) for oral suspension [prescribing information]. New York: Roerig; 2008.
37. Egan TD, Kern SE, Johnson KB, Pace NL The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg. 2003; 97: 72-79.